The delisting risk is removed for now, but traders should monitor future stock performance and liquidity, as reverse splits in micro-cap biotech firms often signal financial stress. Watch for upcoming clinical trial updates as next catalysts.
Price Chart
Executive Summary
XORTX Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after completing a 1-for-5 reverse stock split on April 6, 2026, and trading above the threshold for 10 consecutive days. The company received formal confirmation from Nasdaq on April 20, 2026, avoiding delisting.
Key Facts
- XORTX received a compliance letter from Nasdaq on April 20, 2026, confirming it met the $1.00 minimum bid price requirement.
- The company implemented a 1-for-5 reverse stock split on April 6, 2026, to regain compliance.
- The stock traded at or above $1.00 for 10 consecutive trading days, satisfying Nasdaq Rule 5550(a)(2).
- This resolves a prior deficiency that could have led to delisting.
Financial Impact
No direct financial impact; structural change via reverse split increases share price but reduces shares outstanding proportionally.
Risk Factors
- Ongoing market perception risk due to prior delisting concern.
- Low trading volume and market cap ($3M) may persist despite compliance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002595 |
| Document: f6k_042126.htm | 0001171843-26-002595 |
| Document: 0001171843-26-002595-index-headers.html | 0001171843-26-002595 |
| Document: 0001171843-26-002595-index.html | 0001171843-26-002595 |
| Document: 0001171843-26-002595.txt | 0001171843-26-002595 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $0.9100 (−35.46%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.9100 (−52.60%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.9100 (−52.60%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $0.9100 (+60.61%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $0.9100 (−61.08%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $0.9100 (−57.87%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $0.9100 (−55.83%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.9100 (−58.45%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.9100 (−58.45%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $0.9100 (+60.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers